Mediaboss Marketing

ATLANTA & NEW YORK, June 11, 2012 (GLOBE NEWSWIRE) -- Remark Media, Inc. (NASDAQ: MARK), a global digital media company, announces today four new additions to its management team in the areas of product, editorial, marketing and sales. The primary focus of the new management team members will be the growth and development of Remark Media's new product DimeSpring.com, a personal finance site that brings together leading financial experts to participate in an empowering conversation with consumers. The site offers interactive content, social sharing, and tools that enable users to take action on what they've learned.

"These new team members will play a major role in the implementation of the company's strategy of developing new proprietary content websites, starting in the personal finance sector with a focus on DimeSpring.com," said Remark Media CEO Carrie Ferman. "In addition, they will accelerate the efforts of our mission to provide immersive digital experiences that inform, entertain and inspire audiences worldwide."

Rob Sheppe, named Vice President of Product will drive product innovation efforts, as well as the implementation of a community-driven platform strategy. Prior to joining Remark Media, Sheppe served as Director, Product at Discovery Digital Media where he led platform-wide initiatives across Discovery Communication's portfolio for leading digital brands such as HowStuffWorks.com.

Mike Benzie joins as Director of Editorial Operations, responsible for managing content development. Benzie comes to the company from Yahoo!, where he helped launch and direct local news efforts. Previously, Benzie was an editor at the Atlanta Journal-Constitution, where he led the multimedia and photo departments and the AJC.com digital producer team.

Valerie Brown named Senior Director of Marketing joins from Time Out North America and will lead company-wide multi-platform marketing and social media efforts, including the activation of strategic digital partnerships. Prior to Time Out North America, Brown held key consumer and digital marketing positions at The Bravo Network and AgencyNet Interactive.

Kimberly Leon will serve as National Sales Director. Leon will be responsible for advancing the company's digital business development efforts, including the implementation of content and sponsorship focused advertising partnerships. Prior to joining Remark Media, Leon held management sales roles at CFO Publishing and Dow Jones.

About Remark Media:

Remark Media, Inc. (Nasdaq: MARK) is a global digital media company focused on creating destinations that merge engaging content with rich social interaction. Remark Media is the exclusive digital publisher in China and Brazil for translated content from HowStuffWorks.com, a subsidiary of Discovery Communications, and in China for certain content from World Book. The Company's leading brands, BoWenWang (bowenwang.com.cn) and ComoTudoFunciona (hsw.com.br), provide readers in China and Brazil with thousands of articles about how the world around them works, serving as destinations for credible, easy-to-understand reference information. Remark Media is also a founding partner and developer of the U.S.-based product Sharecare, a highly searchable social Q&A healthcare platform organizing and answering the questions of health. The Company is headquartered in Atlanta with additional operations in New York, Beijing and Sao Paulo. Additional information is available on its corporate website at remarkmedia.com.

Forward-Looking Statements:

This press release contains "forward-looking statements", as defined in Section 27A of the Securities Act of 1993, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be in the future tense, and often include words such as "anticipate", "expect", "project", "believe", "plan", "estimate", "intend", "will" and "may". These statements are based on current expectations, but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of Remark Media. Relevant risks and uncertainties include those referenced in Remark Media's filings with the SEC, and include but are not limited to: our losses and need to raise capital; successfully developing and launching new digital media properties; restrictions on intellectual property under agreements with Sharecare and third parties; challenges inherent in developing an online business; reliance on key personnel; general industry conditions and competition; and general economic conditions, such as advertising rate, interest rate and currency exchange rate fluctuations. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. Remark Media assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

See more here:
Remark Media Names New Product, Editorial, Marketing and Sales Management Team

PHILADELPHIA, June 11, 2012 /PRNewswire/ --Halozyme Therapeutics, Inc. (HALO) today announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes. The study met its primary endpoint of A1C non-inferiority (A1C is a measure of average blood sugar over three months). Further, data from the study indicated that rHuPH20 reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. These findings were presented in an oral presentation at the 72nd Scientific Sessions of the American Diabetes Association (ADA) on Monday, June 11 from 6:15 - 6:30 PM EDT.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"There is a real need for faster-acting mealtime insulins. By accelerating the absorption and action of prandial insulins, rHuPH20 may help reduce mealtime glucose fluctuations that make managing diabetes difficult," said Irl B. Hirsch, M.D., Professor of Medicine, Diabetes Treatment and Teaching Chair, University of Washington School of Medicine. "This faster-in, faster-out profile may also attenuate the risk of hypoglycemia. In this study, improved control of mealtime glucose significantly reduced hypoglycemic events in patients receiving treatments with the rHuPH20 enzyme. The data further indicated that Halozyme's ultrafast insulin formulations moderate glucose swings, thus more closely mimicking the effects of endogenous insulin and, if approved, could ultimately help patients with diabetes live healthier lives."

The study compared two rapid acting insulin analog products (lispro or aspart), formulated with rHuPH20 (lispro-PH20 and aspart-PH20, each an Analog-PH20), to an active comparator (lispro alone). The study met the primary endpoint, showing that the Analog-PH20 formulations were non-inferior for A1C, compared to lispro alone (0.4% margin) with no treatment difference (95% CI -.05, +.15). Patient groups in all treatment arms of this study achieved excellent blood glucose control, with endpoint A1C values <6.9%. Data from the study also showed that mean post-meal glycemic excursions (measured at 90 minutes) in the patient groups treated with Analog-PH20 were reduced by 82 percent (p=.0045), with more patients consistently achieving post-prandial glucose targets for at least two-thirds of their meals, as compared with the patient group treated with lispro alone. For those patient groups treated with Analog-PH20, overall hypoglycemic rates as defined by the ADA (glucose <70 mg/dL) were reduced by 5 percent (p=.035) and hypoglycemic events as defined by a more stringent definition (glucose <56 mg/dL) by 7 percent (p=.044), as compared with the patient group treated with lispro alone.

Additionally, over the 12 week study period total daily insulin dose with the Analog-PH20 treatment groups was comparable (54+27 U vs. 56+27 U, p=.057) as was weight change (-0.25 lbs. vs. +0.10 lbs., p=.27), compared with the patient group treated with lispro alone. Adverse events were also comparable between treatments, with no meaningful difference in adverse events, immunogenicity or injection site pain and Analog-PH20 was well tolerated. Treatment phase severe adverse events were limited to hypoglycemia, which occurred in two subjects treated with lispro alone.

Study Design

This 30 week, randomized, double-blind, two-way cross-over safety and efficacy study compared subcutaneously injected Analog-PH20 versus lispro alone in patients with Type 1 diabetes who were an average age of 43+14 years and had been treated with insulin for> 12 months. The study enrolled 117 patients with an average Body Mass Index (BMI) of 27.3+4.0, and A1C of 7.0+.5 percent. After a four to six week run-in period using prandial glulisine plus twice-daily glargine, patients were randomized to lispro-PH20 or aspart-PH20 versus lispro alone for two, 12-week intensive management periods. Prandial therapy was administered immediately before meals. The primary endpoint of the study was A1C non-inferiority. Secondary outcomes included rates of hypoglycemia, insulin dose, change in body weight, along with blood glucose measures.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at http://www.halozyme.com.

Safe Harbor Statement

View post:
Halozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 ...

Cookies are small data files which are sent to your browser (Internet Explorer, Firefox, Chrome etc) from a website you visit. They are stored on your electronic device.

This is a type of cookie which is collected by Adobe Flash media player (it is also called a Local Shared Object) - a piece of software you may already have on your electronic device to help you watch online videos and listen to podcasts.

Yes there are a number of options available, you can set your browser either to reject all cookies, to allow only "trusted" sites to set them, or to only accept them from the site you are currently on.

However, please note - if you block/delete all cookies, some features of our websites, such as remembering your login details, or the site branding for your local newspaper may not function as a result.

The types of cookies we, our ad network and technology partners use are listed below:

A tool used by some of our advertisers to target adverts to you based on pages you have visited in the past. To opt out of this type of targeting you can visit the 'Your Online Choices' website by clicking here.

Our sites contain advertising from Google; these use cookies to ensure you get adverts relevant to you. You can tailor the type of ads you receive by visiting here or to opt out of this type of targeting you can visit the 'Your Online Choices' website by clicking here.

This is used to help us identify unique visitors to our websites. This data is anonymous and we cannot use this to uniquely identify individuals and their usage of the sites.

This comes from our ad serving technology and is used to track how many times you have seen a particular ad on our sites, so that you don't just see one advert but an even spread. This information is not used by us for any other type of audience recording or monitoring.

ComScore monitor and externally verify our site traffic data for use within the advertising industry. Any data collected is anonymous statistical data and cannot be traced back to an individual.

Go here to read the rest:
Join us @coleraine_times

Govt info officers urged to use social networking

ILOILO City Philippine Information Agency (PIA) Region 6 Director Janet Mesa urged government information officers to use online social networking in information dissemination.

Move on to social networking through the use of the internet and be on social networking sites such as Facebook, Twitter and MySpace. Open your municipalities to these new exciting outlets of information and use them effectively to disseminate government information, said Mesa during the induction of the new set of officers of the Association of Government Information Officers in Iloilo held at Damires Hills in Janiuay, Iloilo.

Mesa also urged them to be consistent in their attendance in meetings and submission of accomplishments of their agencies and local government units for dissemination.

Mesa said a municipality is active and efficient not only because of the leadership of the local chief executive but also because of the information support given by the information officers.

The more you talk, the more people will know and support development, said Mesa as she congratulated the new set of officers headed by Juvy Gaton, head of the Information Division of the Department of Agriculture Regional Field Unit 6.

Janiuay Mayor Frankie Locsin inducted Gaton and the other officers that included:

* David Israel Sinay of the Department of Environment and Natural Resources 6 vice president for National Government Agencies

* Susan Jovero of the municipality of Pavia vice president for local government units

* May Castillo of the Department of Social Welfare and Development 6 secretary

The rest is here:
Gov’t info officers urged to use social networking

Scientists say they have found a key piece in the puzzle as to why a tiny minority of individuals infected with HIV have a natural ability to fight off the deadly AIDS virus.

In a study they say holds promise for an HIV vaccine, researchers from four countries have reported the secret lies not in the number of infection-killing cells a person has, but in how well they work.

Only about one person in 300 has the ability to control the human immunodeficiency virus (HIV) without drugs, using a strain of 'killer' cells called cytotoxic T lymphocyte (CTL) cells, previous research has found.

Taking that discovery further, scientists from the United States, Canada, Japan and Germany reported that the strain has molecules called receptors that are better able to identify HIV-infected white blood cells for attack.

Until now, it was well known that people with HIV 'have tonnes of these killer cells', Bruce Walker, an infectious diseases expert at the Ragon Institute in Massachusetts, told AFP.

'We have been scratching our heads since then, asking how, with so many killer cells around, people are getting AIDS. It turns out there is a special quality that makes them (some cells) better at killing.'

The study looked at 10 infected people, of whom five took antiretroviral drugs to keep HIV under control while five were so-called elite controllers who remained naturally healthy.

HIV kills a type of white blood cell called CD4, leaving people with AIDS wide open to other, opportunistic and potentially deadly infections.

'What we found was that the way the killer cells are able to see infected cells and engage them was different,' said Walker.

'It is not just that you need a killer cell, what you need is a killer cell with a (T cell) receptor that is particularly good at recognising the infected cell. This gives us a way to understand what it is that makes a really good killer cell.'

Link:
Secret of HIV's natural born killers out